Table 1.
Characteristics of the three groups of vaccinated subjects.
| Characteristic | All | ChAd/ChAd | BNT/BNT | ChAd/BNT | |
|---|---|---|---|---|---|
| n = 1248 | n = 184 (15%) | n = 985 (79%) | n = 79 (6%) | ||
| Gender | Male | 412 (33%) | 83 (45%) | 292 (30%) | 37 (47%) |
| Female | 836 (67%) | 101 (55%) | 693 (70%) | 42 (53%) | |
| Age | Years (median, IQR) | 52 (44–59) | 55 (48–61) | 51 (43–58) | 52 (46–57) |
| Interval between prime and boost dose | Days (median, IQR) | 74 (74–74) | 25 (21–35) | 83 (83–83) | |
| Interval between boost dose and antibody titer test | Days (median, IQR) | 61 (57–65) | 60 (60–60) | 61 (55–67) | |
ChAd/ChAd denotes a ChAdOx1 nCoV-19 (ChAd) COVID-19 vaccine (Vaxzevria, AstraZeneca) for prime and boost doses. BNT/BNT denotes BNT162b2 (BNT) COVID-19 vaccine (Comirnaty, Pfizer–BioNTech) for prime and boost doses. ChAd/BNT denotes a ChAd vaccine for prime dose and a BNT vaccine for boost dose.